Tempest Therapeutics Inc (TPST)

$6.90 +0.29 (4.39%)
Market Cap 24.34M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 220,100
Avg Vol 133,732
Day's Range N/A - N/A
Shares Out 3.68M
Stochastic %K 8%
Beta -2.00
Analysts Sell
Price Target $9.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Slapshot22
Slapshot22 Jun. 17 at 1:22 AM
$TPST This one is going to be an interesting play. I don't believe in buying stocks strictly for BO potential. But I look at the assets ... and then the MC of $24M ... and just wonder why this one is not swallowed up. And what the BO negotiated price would look like. I keep telling myself I am buying on Value here, but man, I expect almost any day this one will be gone. Should be an interesting 2H of '25 (assuming we make it that far). Picked up a few more shares today, staying long. GLA.
1 · Reply
HectorNumba9
HectorNumba9 Jun. 17 at 12:27 AM
$TPST Accumlate⏳
0 · Reply
jro23
jro23 Jun. 17 at 12:16 AM
$TPST I've noticed the past few trading days that the last trade of the day bumps up the price to 9.99. Don't know exactly what that means, if anything, but have not seen that prior to the execs transitioning to consulting roles.
1 · Reply
Kels_11
Kels_11 Jun. 16 at 11:44 PM
$TPST *I'm fine with that as well.
0 · Reply
Kels_11
Kels_11 Jun. 16 at 11:35 PM
$TPST Would be nice to see this walk back into the mid $7S by the wend of this week and don't mind if it decides to get boring there until more is revealed. But if they decide to keep offering cheapies in the mid 6s in five with that as well.
0 · Reply
GreylockSec
GreylockSec Jun. 16 at 11:08 PM
$TPST ...With all the bad news piling up for alternative immunotherapies from multiple anti-TIGIT trials, Roche may suddenly want to now take a harder look at buying out Tempest for the extra 6-months of (phase-2 only so far) mOS offered by TPST-1120... -- Fierce Biotech, dated 6-13-25 -- " The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble" : "...Even executives at Roche, whose tiragolumab appeared to buck the trend with a caveated phase 3 win in esophageal cancer in 2024, reaffirmed earlier this year that “we stopped all of the tiragolumab trials that we could stop, and those that couldn't be stopped are just running out....if you ask 99% of average investors, generalists or specialists, I think they’ll tell you it's dead,” she added...." Suddenly Tempest could be a hot ticket again 🌟 -
2 · Reply
lousjamsession
lousjamsession Jun. 16 at 10:34 PM
$TPST that's a major improvement because we were at $16.92 ever since the reverse split.
0 · Reply
gainsareus
gainsareus Jun. 16 at 10:22 PM
$TPST come on TPST, I need a good return here🙏
2 · Reply
lousjamsession
lousjamsession Jun. 16 at 10:12 PM
$TPST new cost avg $9.97 keep it going, guys.
0 · Reply
TommyHulk
TommyHulk Jun. 16 at 9:07 PM
$TPST It’s about time, and we just want to get it over with. Come on, Brady, make it final and give us the news.
2 · Reply
Latest News on TPST
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 5 days ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 11 days ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 4 weeks ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 7 weeks ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 2 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 2 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 2 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 2 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 3 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 4 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 4 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 5 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 7 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 7 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 8 months ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 8 months ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 9 months ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 10 months ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 10 months ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 11 months ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 1 year ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 1 year ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 1 year ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 1 year ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 1 year ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 1 year ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest to Present at the Jefferies Global Healthcare Conference

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 4:05 PM EST - 2 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 8, 2022, 8:00 AM EST - 2 years ago

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

Oct 6, 2022, 8:00 AM EDT - 2 years ago

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

Slapshot22
Slapshot22 Jun. 17 at 1:22 AM
$TPST This one is going to be an interesting play. I don't believe in buying stocks strictly for BO potential. But I look at the assets ... and then the MC of $24M ... and just wonder why this one is not swallowed up. And what the BO negotiated price would look like. I keep telling myself I am buying on Value here, but man, I expect almost any day this one will be gone. Should be an interesting 2H of '25 (assuming we make it that far). Picked up a few more shares today, staying long. GLA.
1 · Reply
HectorNumba9
HectorNumba9 Jun. 17 at 12:27 AM
$TPST Accumlate⏳
0 · Reply
jro23
jro23 Jun. 17 at 12:16 AM
$TPST I've noticed the past few trading days that the last trade of the day bumps up the price to 9.99. Don't know exactly what that means, if anything, but have not seen that prior to the execs transitioning to consulting roles.
1 · Reply
Kels_11
Kels_11 Jun. 16 at 11:44 PM
$TPST *I'm fine with that as well.
0 · Reply
Kels_11
Kels_11 Jun. 16 at 11:35 PM
$TPST Would be nice to see this walk back into the mid $7S by the wend of this week and don't mind if it decides to get boring there until more is revealed. But if they decide to keep offering cheapies in the mid 6s in five with that as well.
0 · Reply
GreylockSec
GreylockSec Jun. 16 at 11:08 PM
$TPST ...With all the bad news piling up for alternative immunotherapies from multiple anti-TIGIT trials, Roche may suddenly want to now take a harder look at buying out Tempest for the extra 6-months of (phase-2 only so far) mOS offered by TPST-1120... -- Fierce Biotech, dated 6-13-25 -- " The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble" : "...Even executives at Roche, whose tiragolumab appeared to buck the trend with a caveated phase 3 win in esophageal cancer in 2024, reaffirmed earlier this year that “we stopped all of the tiragolumab trials that we could stop, and those that couldn't be stopped are just running out....if you ask 99% of average investors, generalists or specialists, I think they’ll tell you it's dead,” she added...." Suddenly Tempest could be a hot ticket again 🌟 -
2 · Reply
lousjamsession
lousjamsession Jun. 16 at 10:34 PM
$TPST that's a major improvement because we were at $16.92 ever since the reverse split.
0 · Reply
gainsareus
gainsareus Jun. 16 at 10:22 PM
$TPST come on TPST, I need a good return here🙏
2 · Reply
lousjamsession
lousjamsession Jun. 16 at 10:12 PM
$TPST new cost avg $9.97 keep it going, guys.
0 · Reply
TommyHulk
TommyHulk Jun. 16 at 9:07 PM
$TPST It’s about time, and we just want to get it over with. Come on, Brady, make it final and give us the news.
2 · Reply
jyc990
jyc990 Jun. 16 at 8:59 PM
$TPST a good accumulating day for me. Hope I'm not too early, I was trying to wait a few more weeks but all this talk of change of control and pre-market $35... Didn't want to wake up tmrw and see this at like $50+
1 · Reply
lousjamsession
lousjamsession Jun. 16 at 7:48 PM
$TPST
0 · Reply
ManiacalSlug
ManiacalSlug Jun. 16 at 7:00 PM
$TPST The Count Says We Are Heading to 7s!!
0 · Reply
Ueberschlaefer
Ueberschlaefer Jun. 16 at 6:47 PM
$TPST there are have been multiple pharma BOs in the past couple of days. this company should be at the top of the list for most oncology BP companies. as i've posted before, may/june are the months which see the largest number of BOs. other times of the year are quieter. brady knows what he's doing.
1 · Reply
Ueberschlaefer
Ueberschlaefer Jun. 16 at 6:24 PM
$TPST my plan was for this to keep declining so i could average down. apparently, *they* figured it out and are actively working against me.
2 · Reply
Ueberschlaefer
Ueberschlaefer Jun. 16 at 6:23 PM
$TPST my 500 share purchase caused a rally. we broke 7. you're welcome.
1 · Reply
Letsinvest2024
Letsinvest2024 Jun. 16 at 6:20 PM
$TPST imagine if it goes up 500% in a single day 🤩
1 · Reply
Auphiliate
Auphiliate Jun. 16 at 6:07 PM
$TPST Relatively small position here since a couple of years ago. Added a bit more post rs. 😊
0 · Reply
RoachlessSack
RoachlessSack Jun. 16 at 6:05 PM
$TPST imagine selling at $199,999
1 · Reply
lousjamsession
lousjamsession Jun. 16 at 5:56 PM
$TPST apparently they didn't want it going down any further curved midway to 30. They like $7 as the bottom
1 · Reply
Michl2000
Michl2000 Jun. 16 at 5:44 PM
$TPST you're completely right - but nevertheless it feels more comfortable at least for me if the share price is a little bit more elevated.
1 · Reply
Kels_11
Kels_11 Jun. 16 at 5:43 PM
$TPST 💥 or bust nothing in between for me... holding until then
0 · Reply